Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 11, 2022 Expiration: May 10, 2023
Start Activity
Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
This activity is supported by an educational grant from
Lilly
Joyce O'Shaughnessy, MD
Program Director
Sara Tolaney, MD, MPH
Program Director

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
  • Evaluate the clinical validity, utility, and differences among Ki67 assessment techniques
  • Integrate best practices for Ki67 testing methodology, standardization, and reporting
  • Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
  • Foster collaborative discussions and workflows among oncologists, pathologists, and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
  • Identify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trials 

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, Aptitude, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Puma, Prime, Roche, Seattle Genetics, and Syndax.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharma, AstraZeneca, Athenex, BeyondSpring, Bristol-Myers Squibb, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech, Immunomedics/Gilead, Infinity, Lilly, Mersana, Novartis, OncoPep, OncoSec, OncXerna, Pfizer, Puma, Sanofi, Samsung Bioepsis, Seattle Genetics, Zymeworks, and Zentalis.

Staff

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kelly Brandt, PharmD
Kelly Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN has received speaker fees from BMS, Lilly, Sanofi, Regeneron, Gilead, Morphosys, Pfizer, AstraZeneca and DSI.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, pathologists, histotechologists, pharmacists, oncology nurses, and other healthcare professionals who care for patients with breast cancer.

Goal

The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess patients with HR-positive/HER2-negative early breast cancer for Ki67 and accurately report, interpret, and apply results of the testing to optimal therapy selection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-135-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 11, 2022, through May 10, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams
  • CME
  • CE

Loading...
In this on-demand webcast from a live webinar, Joyce O’Shaughnessy, MD, reviews the current data supporting the utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including strategies to promote adherence to oral CDK4/6 inhibitors.
Joyce O'Shaughnessy, MD
Program Director
Sara Tolaney, MD, MPH
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 11, 2022 Expiration: May 10, 2023

Related Content

Video featuring global experts discussing the latest advances in HER2-low advanced breast cancer, including managing the use and safety of antibody–drug conjugates, from Clinical Care Options (CCO)

person default Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 19, 2023 Expired: January 18, 2024

Downloadable slideset on key points from a podcast on how to optimize personalized care of patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 18, 2023

On-demand Clinical Care Options (CCO) webcast: experts discuss how to optimize the personalized care of patients with TNBC

Mark Pegram, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Released: January 12, 2023 Expired: January 11, 2024

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: January 4, 2023
Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
This activity is supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings